A method for analyzing thrombogenic capacity or blood coagulation capacity, the method comprising adding calcium, a blood coagulation factor XII (FXII) inhibitor, and a kallikrein inhibitor to blood collected with a blood collection tube containing sodium citrate, to allow initiation of blood coagulation reaction, is provided. Preferably, heparin, heparan sulfate, and tissue factor are further added to the blood, and thrombogenic capacity or blood coagulation capacity is analyzed.

This invention relates to .sub.1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.

A method for analyzing thrombogenic capacity or blood coagulation capacity, the method comprising adding calcium, a blood coagulation factor XII (FXII) inhibitor, and a kallikrein inhibitor to blood collected with a blood collection tube containing sodium citrate, to allow initiation of blood coagulation reaction, is provided. Preferably, heparin, heparan sulfate, and tissue factor are further added to the blood, and thrombogenic capacity or blood coagulation capacity is analyzed.

This invention relates to .sub.1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.